Get the Stockscreener App
54.55
3.10%
-3.75
Monopar Therapeutics Inc stock is traded at $54.55, with a volume of 47,484.
It is down -3.10% in the last 24 hours and up +3.27% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$58.30
Open:
$57.46
24h Volume:
47,484
Relative Volume:
0.18
Market Cap:
$377.43M
Revenue:
-
Net Income/Loss:
$-19.44M
P/E Ratio:
-15.86
EPS:
-3.4389
Net Cash Flow:
$-10.83M
1W Performance:
-1.93%
1M Performance:
+3.27%
6M Performance:
-10.74%
1Y Performance:
+44.48%
1-Day Range:
$54.24
$58.33
1-Week Range:
$54.24
$64.86
52-Week Range:
$26.05
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
56.48 | 389.59M | 0 | -19.44M | -10.83M | -3.4389 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.60 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.21 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
685.06 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.65 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.62 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Jones Trading Downgrades Monopar Therapeutics (MNPR) - MSN
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC - MarketBeat
(MNPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR) | MNPR Stock News - GuruFocus
Published on: 2026-03-07 04:32:52 - baoquankhu1.vn
Monopar Therapeutics (MNPR) officer Susan Rodriguez submits initial Form 3 - Stock Titan
Monopar Therapeutics (MNPR) CCSO granted 48,728 stock options in new award - Stock Titan
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez - The Globe and Mail
MNPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monopar names Susan Rodriguez as chief commercial officer - Investing.com India
Responsive Playbooks and the MNPR Inflection - Stock Traders Daily
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer - Bitget
Monopar expands leadership team with appointment of seasoned biopharma executive Susan Rodriguez as chief commercial and strategy officer - marketscreener.com
New Monopar (NASDAQ: MNPR) strategy chief to steer ALXN1840 NDA - Stock Titan
Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026 - marketscreener.com
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
BTIG Reiterates Buy Rating for MNPR with $104 Target Price | MNP - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from BTIG Research - MarketBeat
Is Monopar Therapeutics Inc. stock ready for breakoutWeekly Trading Summary & Accurate Intraday Trade Tips - mfd.ru
Can Monopar Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Short Interest & Trade Opportunity Analysis Reports - mfd.ru
Retail Trends: Will Monopar Therapeutics Inc benefit from sector rotationPrice Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Understanding the Setup: (MNPR) and Scalable Risk - Stock Traders Daily
RA Capital reports 9.99% Monopar Therapeutics stake in Schedule 13G/A (MNPR) - Stock Titan
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Monopar Therapeutics (NASDAQ:MNPR) Head to Head Comparison - Defense World
Why Monopar Therapeutics Inc. (1IY0) stock attracts wealthy investors2025 Bull vs Bear & Stepwise Entry and Exit Trade Signals - mfd.ru
MNPR PE Ratio & Valuation, Is MNPR Overvalued - Intellectia AI
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Should I add Monopar Therapeutics Inc. stock to my portfolio2025 Retail Activity & AI Based Trade Execution Alerts - mfd.ru
Stocks showing improved relative strength: Monopar Therapeutics - MSN
The Technical Signals Behind (MNPR) That Institutions Follow - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Rises By 21.1% - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics’ (MNPR) Buy Rating Reaffirmed at BTIG Research - Defense World
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease - TipRanks
BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Zenas BioPharma, Inc. (ZBIO) - The Globe and Mail
Bull Bear: Why is Monopar Therapeutics Inc stock going down2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Chardan Capital Reaffirms Buy Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Precision Trading with Monopar Therapeutics Inc. (MNPR) Risk Zones - Stock Traders Daily
Breakout Move: Will Monopar Therapeutics Inc outperform tech stocksStop Loss & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Market Leaders: Will Monopar Therapeutics Inc outperform tech stocksMarket Rally & Growth Focused Entry Reports - baoquankhu1.vn
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading - The Globe and Mail
JonesTrading Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $130 - 富途牛牛
Monopar Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Monopar Therapeutics: Tiny Cancer-Drug Stock Caught Between Speculation And Survival - AD HOC NEWS
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 28.3% in December - MarketBeat
Fundamentals Check: Why is Monopar Therapeutics Inc stock going downJuly 2025 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):